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AREPORT OF A RANDOMIZED CON-trolledtrial (RCT)shouldcon-vey to the reader, in a trans-parent manner, why the study
was undertaken and how it was con-
ductedandanalyzed.Forexample, a lack
ofadequatelyreportedrandomizationhas
been associated with bias in estimating
the effectiveness of interventions.1,2 To
assess the strengths and limitations of an
RCT, readers need and deserve to know
the quality of its methods. Despite sev-
eral decades of educational efforts, RCTs
still are not being reported adequately.3-6
For example, a review of 122 recently
published RCTs that evaluated the effec-
tiveness of selective serotonin reuptake
inhibitors as first-linemanagement strat-
egy for depression found that only 1
(0.8%) article described randomization
adequately.5 Inadequate reportingmakes
the interpretation of RCT results diffi-
cult if not impossible. Moreover, inad-
equate reporting borders on unethical
practice when biased results receive false
credibility.
HISTORY OF CONSORT
In the mid 1990s, 2 independent initia-
tives to improve the quality of reports
of RCTs led to the publication of the
CONSORT (Consolidated Standards of
Reporting Trials) statement,7 which was
developed by an international group of
clinical trialists, statisticians, epidemi-
ologists, and biomedical editors.
CONSORT has been supported by a
growing number of medical and health
care journals8-11 and editorial groups, in-
cluding the International Committee of
Medical Journal Editors12 (ICMJE, also
known as the Vancouver Group), the
Council of Science Editors (CSE), and
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To comprehend the results of a randomized controlled trial (RCT), readers
must understand its design, conduct, analysis, and interpretation. That goal
can be achieved only through complete transparency from authors. Despite
several decades of educational efforts, the reporting of RCTs needs improve-
ment. Investigators and editors developed the original CONSORT (Consoli-
dated Standards of Reporting Trials) statement to help authors improve re-
porting by using a checklist and flow diagram. The revised CONSORT
statement presented in this article incorporates new evidence and ad-
dresses some criticisms of the original statement.
The checklist items pertain to the content of the Title, Abstract, Introduc-
tion, Methods, Results, and Comment. The revised checklist includes 22 items
selected because empirical evidence indicates that not reporting the infor-
mation is associated with biased estimates of treatment effect or because
the information is essential to judge the reliability or relevance of the find-
ings. We intended the flow diagram to depict the passage of participants
through an RCT. The revised flow diagram depicts information from 4 stages
of a trial (enrollment, intervention allocation, follow-up, and analysis). The
diagram explicitly includes the number of participants, according to each in-
tervention group, included in the primary data analysis. Inclusion of these
numbers allows the reader to judge whether the authors have performed an
intention-to-treat analysis.
In sum, the CONSORT statement is intended to improve the reporting of
an RCT, enabling readers to understand a trial’s conduct and to assess the
validity of its results.
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the World Association of Medical Edi-
tors (WAME). CONSORT is also pub-
lished in Dutch, English, French, Ger-
man, Japanese, and Spanish. It can be
accessed on the Internet, along with
other informat ion about the
CONSORT group.13
The CONSORT statement com-
prises a checklist and flow diagram for
reporting an RCT. For convenience, the
checklist and diagram together are
called simply CONSORT. They are pri-
marily intended for use in writing, re-
viewing, or evaluating reports of simple
2-group parallel RCTs.
Preliminary data indicate that the use
of CONSORT does indeed help to im-
prove the quality of reports of RCTs.14,15
In an evaluation of 71 published RCTs
in 3 journals in 1994, allocation con-
cealment was reported unclearly in 43
(61%) of the trials.14 Four years later, af-
ter these 3 journals required that au-
thors report ing an RCT use
CONSORT, the proportion of articles in
which allocation concealment was re-
ported unclearly had decreased to 30 of
77 (39%; mean difference, −22%; [95%
confidence interval, −38% to −6%]).14
The usefulness of CONSORT is en-
hanced by continuous monitoring of the
biomedical literature; this monitoring
allows CONSORT to be modified de-
pending on the merits of maintaining
or dropping current items and includ-
ing new items. For example, when Mei-
nert16 observed that the flow diagram
did not provide important informa-
tion about the number of participants
who entered each phase of an RCT (en-
rollment, treatment allocation, follow-
up, and data analysis), the diagram was
able to be modified to accommodate the
information. The checklist is similarly
flexible.
This iterative process makes the
CONSORT statement a continually
evolving instrument. While partici-
pants in the CONSORT group and their
degree of involvement vary over time,
members meet regularly to review the
need to refine CONSORT. At the 1999
meeting, participants decided to re-
vise the original statement. This re-
port reflects changes determined by
consensus of the CONSORT group,
partly in response to emerging evi-
dence on the importance of various el-
ements of RCTs.
REVISION OF THE
CONSORT STATEMENT
Thirteen members of the CONSORT
group met in May 1999 with the pri-
mary objective of revising the original
CONSORT checklist and flow dia-
gram, as needed. The group discussed
the merits of including each item in the
light of current evidence. As in devel-
oping the original CONSORT state-
ment, our intention was to keep only
those items deemed fundamental to re-
porting standards for an RCT. Some
items not considered essential may well
be highly desirable and still should be
included in an RCT report even though
they are not included in CONSORT.
Such items include approval of an in-
stitutional ethical review board, sources
of funding for the trial, and a trial reg-
istry number (eg, the International Stan-
dard Randomized Controlled Trial
Number [ISRCTN]) used to register the
RCT at its inception.17
Shortly after the meeting, a revised ver-
sion of the checklist was circulated to the
group for additional comments and feed-
back. Revisions to the flow diagram were
similarly made. All these changes were
discussed when CONSORT partici-
pants met in May 2000, and the revised
statement was finalized shortly after-
ward.
The revised CONSORT statement in-
cludes a 22-item checklist (TABLE) and
a flow diagram (FIGURE). Its primary
aim is to help authors improve the qual-
ity of reports of simple 2-group paral-
lel RCTs. However, the basic philoso-
phy underlying the development of the
statement can be applied to any de-
sign. In this regard, additional state-
ments for other designs will be forth-
coming from the group.13 CONSORT
can also be used by peer reviewers and
editors to identify reports with inad-
equate description of trials and those
with potentially biased results.1,2
During the 1999 meeting, the group
also discussed the benefits of develop-
ing an explanatory document to en-
hance the use and dissemination of
CONSORT. The document is patterned
on reporting of statistical aspects of clini-
cal research18 and was developed to help
facilitate the recommendations of the
ICMJE’s Uniform Requirements for Manu-
scripts Submitted to Biomedical Journals.
Three members of the CONSORT group,
with assistance from members on some
checklist items, drafted an explanation
and elaboration document. That docu-
ment19 was circulated to the group for ad-
ditions and revisions and was last re-
vised after review at the latest CONSORT
group meeting.
CHANGES TO CONSORT
(1) In the revised checklist, a new
column for “paper section and topic”
integrates information from the “sub-
heading” column that was contained in
the original statement.
(2) The “Was it reported?” column
has been integrated into a “reported on
page #” column, as requested by some
journals.
(3) Each item of the checklist is now
numbered and the syntax and order
have been revised to improve the flow
of information.
(4) “Title” and “Abstract” are now
combined in the first item.
(5) While the content of the re-
vised checklist is similar to the origi-
nal, some items that previously were
combined are now separate. For ex-
ample, authors had been asked to de-
scribe “primary and secondary out-
come(s) measure(s) and the minimum
important difference(s), and indicate
how the target sample size was pro-
jected.” In the new version, issues per-
taining to outcomes (item 6) and
sample size (item 7) are separate, en-
abling authors to be more explicit about
each. Moreover, some items request ad-
ditional information. For example, for
outcomes (item 6) authors are asked to
report any methods used to enhance the
quality of measurements, such as mul-
tiple observations.
(6) The item asking for the unit of
randomization (eg, cluster) has been
dropped because specific checklists have
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been developed for reporting cluster
RCTs20 and other design types13 since
publication of the original checklist.
(7) Whenever possible, new evi-
dence is incorporated into the revised
checklist. For example, authors are asked
to be explicit about whether the analy-
sis reported is by intention-to-treat (item
16). This request is based in part on the
observations21 that authors do not ad-
equately describe and apply intention-
to-treat analysis and reports that not pro-
viding this information are less likely to
provide other relevant information, such
as loss to follow-up.22
(8) The revised flow diagram de-
picts information from 4 stages of a trial
(enrollment, intervention allocation,
follow-up, and analysis). The revised
diagram explicitly includes the num-
ber of participants, according to each
intervention group, included in the pri-
mary data analysis. Inclusion of these
numbers lets the reader know whether
the authors have performed an inten-
tion-to-treat analysis,.21-23 Because some
of the information may not always be
Table. Checklist of Items to Include When Reporting a Randomized Trial
Section and Topic Item # Descriptor Reported on Page #
Title and Abstract 1 How participants were allocated to interventions (eg, “random allocation,”
“randomized,” or “randomly assigned”).
Introduction
Background 2 Scientific background and explanation of rationale.
Methods
Participants 3 Eligibility criteria for participants and the settings and locations where the data
were collected.
Interventions 4 Precise details of the interventions intended for each group and how and
when they were actually administered.
Objectives 5 Specific objectives and hypotheses.
Outcomes 6 Clearly defined primary and secondary outcome measures and, when
applicable, any methods used to enhance the quality of measurements (eg,
multiple observations, training of assessors).
Sample size 7 How sample size was determined and, when applicable, explanation of any
interim analyses and stopping rules.
Randomization
Sequence generation 8 Method used to generate the random allocation sequence, including details of
any restriction (eg, blocking, stratification).
Allocation concealment 9 Method used to implement the random allocation sequence (eg, numbered
containers or central telephone), clarifying whether the sequence was
concealed until interventions were assigned.
Implementation 10 Who generated the allocation sequence, who enrolled participants, and who
assigned participants to their groups.
Blinding (masking) 11 Whether or not participants, those administering the interventions, and those
assessing the outcomes were blinded to group assignment. If done, how the
success of blinding was evaluated.
Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); methods
for additional analyses, such as subgroup analyses and adjusted analyses.
Results
Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended).
Specifically, for each group report the numbers of participants randomly
assigned, receiving intended treatment, completing the study protocol, and
analyzed for the primary outcome. Describe protocol deviations from study as
planned, together with reasons.
Recruitment 14 Dates defining the periods of recruitment and follow-up.
Baseline data 15 Baseline demographic and clinical characteristics of each group.
Numbers analyzed 16 Number of participants (denominator) in each group included in each analysis
and whether the analysis was by “intention-to-treat.” State the results in
absolute numbers when feasible (eg, 10/20, not 50%).
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each
group, and the estimated effect size and its precision (eg, 95% confidence
interval).
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including
subgroup analyses and adjusted analyses, indicating those prespecified and
those exploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
Comment
Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources of
potential bias or imprecision, and the dangers associated with multiplicity of
analyses and outcomes.
Generalizability 21 Generalizability (external validity) of the trial findings.
Overall evidence 22 General interpretation of the results in the context of current evidence.
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known and to accommodate other in-
formation, the structure of the flow dia-
gram may need to be modified for a par-
ticular trial. Inclusion of the participant
flow diagram in the report is strongly
recommended but may be unneces-
sary for simple trials, such as those with-
out any participant withdrawals or
dropouts.
COMMENT
Specifically developed to guide au-
thors about how to improve the qual-
ity of reporting of simple 2-group par-
allel RCTs, CONSORT encourages
transparency in reporting the meth-
ods and results so that reports of RCTs
can be interpreted both readily and ac-
curately. However, CONSORT does not
address other facets of reporting that
also require attention, such as scien-
tific content and readability of RCT re-
ports. Some authors, in their enthusi-
asm to use CONSORT, have modified
the checklist.24 We recommend against
such modifications because they may
be based on a different process than the
one used by the CONSORT group.
The use of CONSORT seems to re-
duce (if not eliminate) inadequate re-
porting of RCTs.14,15 Potentially, the use
of CONSORT should positively influ-
ence the manner in which RCTs are con-
ducted. Granting agencies have noted
this potential relationship and, in at least
1 case,25 have encouraged grantees to
consider in their application how they
have dealt with the CONSORT items.
The evidence-based approach used
to develop CONSORT also has been
used to develop standards for report-
ing meta-analyses of randomized tri-
als,26 meta-analyses of observational
studies,27 and diagnostic studies (Jeroen
Lijmer, MD, written communication,
October 2000). Health economists also
have started to develop reporting stan-
dards28 to help improve the quality of
their reports.29 The intent of all these
initiatives is to improve the quality of
reporting of biomedical research30 and
by doing so to bring about more effec-
tive health care.
The revised CONSORT statement will
replace the original one in the journals
and groups that already support it.
Journals that do not yet support
CONSORT may do so by registering on
the CONSORT Web site.13 To convey to
authors the importance of improved
quality in the reporting of RCTs, we en-
courage supporting journals to refer-
ence the revised CONSORT statement
and the CONSORT Internet address13 in
their “Instructions to Authors.” Be-
cause the journals publishing the re-
vised CONSORT statement have waived
copyright protection, CONSORT is now
widely accessible to the biomedical com-
munity. The CONSORT checklist and
flow diagram can also be accessed at the
CONSORT Web site.13
A lack of clarification of the mean-
ing and rationale for each checklist item
in the original CONSORT statement has
been remedied with the development
of the CONSORT explanation and
elaboration document,19 which also can
be found on the CONSORT Web site.13
This document reports the evidence on
which the checklist items are based, in-
cluding the references, which had an-
notated the checklist items in the pre-
vious version. We encourage journals
to also include reference to this docu-
ment in their Instructions to Authors.
Emphasizing the evolving nature of
CONSORT, the CONSORT group in-
vites readers to comment on the up-
dated checklist and flow diagram
through the CONSORT Web site.13
Comments and suggestions will be col-
lated and considered at the next meet-
ing of the group in 2001.
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